<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<meta property="og:title" content="Bibliography using Zotero | Portfolio Pedro de Bos" />
<meta property="og:type" content="book" />







<meta name="description" content="Bibliography using Zotero | Portfolio Pedro de Bos">

<title>Bibliography using Zotero | Portfolio Pedro de Bos</title>

<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="libs/bootstrap-3.3.5/css/bootstrap.min.css" rel="stylesheet" />
<script src="libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="libs/navigation-1.1/tabsets.js"></script>
<script src="libs/htmlwidgets-1.5.4/htmlwidgets.js"></script>
<link href="libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="libs/datatables-binding-0.23/datatables.js"></script>
<link href="libs/dt-core-1.11.3/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="libs/dt-core-1.11.3/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="libs/dt-core-1.11.3/js/jquery.dataTables.min.js"></script>
<link href="libs/crosstalk-1.2.0/css/crosstalk.min.css" rel="stylesheet" />
<script src="libs/crosstalk-1.2.0/js/crosstalk.min.js"></script>


<style type="text/css">code{white-space: pre;}</style>
<style type="text/css">
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
  { counter-reset: source-line 0; }
pre.numberSource code > span
  { position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
  { content: counter(source-line);
    position: relative; left: -1em; text-align: right; vertical-align: baseline;
    border: none; display: inline-block;
    -webkit-touch-callout: none; -webkit-user-select: none;
    -khtml-user-select: none; -moz-user-select: none;
    -ms-user-select: none; user-select: none;
    padding: 0 4px; width: 4em;
    color: #aaaaaa;
  }
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa;  padding-left: 4px; }
div.sourceCode
  {   }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } /* Alert */
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } /* Annotation */
code span.at { color: #7d9029; } /* Attribute */
code span.bn { color: #40a070; } /* BaseN */
code span.bu { } /* BuiltIn */
code span.cf { color: #007020; font-weight: bold; } /* ControlFlow */
code span.ch { color: #4070a0; } /* Char */
code span.cn { color: #880000; } /* Constant */
code span.co { color: #60a0b0; font-style: italic; } /* Comment */
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } /* CommentVar */
code span.do { color: #ba2121; font-style: italic; } /* Documentation */
code span.dt { color: #902000; } /* DataType */
code span.dv { color: #40a070; } /* DecVal */
code span.er { color: #ff0000; font-weight: bold; } /* Error */
code span.ex { } /* Extension */
code span.fl { color: #40a070; } /* Float */
code span.fu { color: #06287e; } /* Function */
code span.im { } /* Import */
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } /* Information */
code span.kw { color: #007020; font-weight: bold; } /* Keyword */
code span.op { color: #666666; } /* Operator */
code span.ot { color: #007020; } /* Other */
code span.pp { color: #bc7a00; } /* Preprocessor */
code span.sc { color: #4070a0; } /* SpecialChar */
code span.ss { color: #bb6688; } /* SpecialString */
code span.st { color: #4070a0; } /* String */
code span.va { color: #19177c; } /* Variable */
code span.vs { color: #4070a0; } /* VerbatimString */
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } /* Warning */
</style>
<style type="text/css">
  pre:not([class]) {
    background-color: white;
  }
</style>


<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="style.css" type="text/css" />

<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
code {
  color: inherit;
  background-color: rgba(0, 0, 0, 0.04);
}
img {
  max-width:100%;
  height: auto;
}
/* show arrow before summary tag as in bootstrap
TODO: remove if boostrap in updated in html_document (rmarkdown#1485) */
details > summary {
  display: list-item;
  cursor: pointer;
}
</style>
</head>

<body>

<div class="container-fluid main-container">


<div class="row">
<div class="col-sm-12">
<!--bookdown:toc:end-->
<!--bookdown:toc:start-->
</div>
</div>
<div class="row">
<div class="col-sm-12">
<div id="bibliography-using-zotero" class="section level1">
<h1>Bibliography using Zotero</h1>
<body id="start">
<div class="topnav">
<p><a href='index.html#Frontpage'>Frontpage</a>
<a href='data-visualisation.html#data-visualisation'>Data visualisation</a>
<a href='parametized-data-germany.html#parametized-data'>Parametizing data</a>
<a href='directory-structure.html#directory-structure'>Directory structure</a>
<a href='creating-a-r-package.html#creating-a-r-package'>R-package</a>
<a href='sql.html#SQL'>SQL</a>
<a class="active" href='bibliography-using-zotero.html#Bibliography using Zotero'>Zotero</a>
<a href='open-reproductibility-analysis.html#open-reproductibility-analysis'>Reproductibility</a>
<a href='future-endeavours.html#future-endeavours'>Future endeavours</a>
<a href='free-research-project-index.html#free-research-project'> Free research (Machine learning)</a>
<a href='cv.html#cv'>CV</a>
<a href='bibliography.html#bibliography'>Bibliography</a></p>
</div>
<p> </p>
<p>To prove I’m able to use bibliography applications like “Zotero”, a small introduction to my current projecticum will be written, and a bibliography will be automaticall generated using Zotero.</p>
<div id="projecticum-liquid-biopsies-sequencing-analysis-project" class="section level3">
<h3>Projecticum “Liquid biopsies sequencing analysis project”</h3>
<p>For projecticum “Liquid biopsies”, a collaboration between the Princes Maxima Centre for child oncology and the university of applied sciences Utrecht, the data analysis of Neuroblastoma and the comparison of tumour-biopsy sequencing data and cell-free sequencing data was central.</p>
</div>
<div id="neuroblastoma" class="section level3">
<h3>Neuroblastoma</h3>
<p>Neuroblastoma is a form of cancer formed by cells derived from the neural crest, tumours can be generated in any part of the sympathetic neural system. Because of their origin in developing tissues, neuroblastomas mostly occur in young children, the median age being 17 months old. Symptoms vary based on location of the tumour: they usually appear upon adrenal medulla or the paraspinal ganglia, but they can also appear upon the liver or in bone marrow <span class="citation">(<a href="#ref-marisRecentAdvancesNeuroblastoma2010" role="doc-biblioref">Maris 2010</a>)</span>. Neuroblastoma is distinct from other tumour due to their range of clinical behaviour. In some patients the disease can spontaneously regress, in others the disease is metastatic and highly-aggressive <span class="citation">(<a href="#ref-louisNeuroblastomaMolecularPathogenesis2015" role="doc-biblioref">Louis and Shohet 2015</a>)</span>. Patients with neuroblastoma can be assigned a pre-treatment risk classification: either low, intermediate, or high-risk <span class="citation">(<a href="#ref-monclairInternationalNeuroblastomaRisk2009" role="doc-biblioref">Monclair et al. 2009</a>)</span>. These risk levels are based on histological data <span class="citation">(<a href="#ref-monclairInternationalNeuroblastomaRisk2009" role="doc-biblioref">Monclair et al. 2009</a>)</span>, but also on specific genomic mutations found during tumour biopsy sequencing <span class="citation">(<a href="#ref-louisNeuroblastomaMolecularPathogenesis2015" role="doc-biblioref">Louis and Shohet 2015</a>)</span>.</p>
<p>The use of genomic information in the prognosis of neuroblastoma risk classification looks at multiple factors: upregulation of the <em>MYCN</em> proto-oncogene (defined as more than 10 copies of the gene) can be found in 20% of overall cases and generally carries a poor prognosis <span class="citation">(<a href="#ref-louisNeuroblastomaMolecularPathogenesis2015" role="doc-biblioref">Louis and Shohet 2015</a>)</span>. Furthermore, loss-of-function in chromosomes 1p36 <span class="citation">(<a href="#ref-whiteRegionConsistentDeletion1995" role="doc-biblioref">P. S. White et al. 1995</a>)</span> and 11q <span class="citation">(<a href="#ref-mlakar11qDeletionNeuroblastoma2017" role="doc-biblioref">Mlakar et al. 2017</a>)</span> or gain of function at chromosome 17q <span class="citation">(<a href="#ref-abelGainChromosomeArm1999" role="doc-biblioref">Abel et al. 1999</a>)</span> is also frequently seen in aggressive cases of neuroblastoma. Using these genomic markers can thus be used to predict the severity of the disease in patients <span class="citation">(<a href="#ref-whittleOverviewRecentAdvances2017" role="doc-biblioref">Whittle et al. 2017</a>)</span>. However, currently, in order to perform an genomic analysis a tumour biopsy needs to be performed. These biopsies risk complications for the patients due to the general young nature of the patient, risking problems with anaesthesia, excess bleeding, infections or other complications <span class="citation">(<a href="#ref-paraboschiRoleBiopsyWorkup2021a" role="doc-biblioref">Paraboschi et al. 2021</a>)</span>.</p>
</div>
<div id="liquid-biopsies" class="section level3">
<h3>Liquid biopsies</h3>
<p>Liquid biopsies, the subject of this project, might be able to alleviate some of the pressure off of tumour biopsies. Blood samples from neuroblastoma patients contain circulating tumour cells, which can be studied via genomics/proteomics techniques. This is particularly helpful for neuroblastoma patients where tumour cells are not available from the main tumour, or where these are not sufficient for a genomics study. Due to the higher amount of circulating cell-free DNA, liquid biopsies might prove to be a way to monitor the progression of disease in neuroblastoma patients while performing a smaller amount of invasive surgeries <span class="citation">(<a href="#ref-espositoNeuroblastomaTreatmentPostgenomic2017" role="doc-biblioref">Esposito et al. 2017</a>)</span>. In order for liquid biopsies to be used as a monitoring technique next to tumour biopsies, however, it needs to be proven that liquid biopsy genetic profiles mirror the genetic profiles of tumour biopsies. Although there has been research into this matter <span class="citation">(<a href="#ref-rifatbegovicEnrichedBoneMarrow2015" role="doc-biblioref">Rifatbegovic et al. 2015</a>)</span>, it is not yet been proven to the point where it is part of routine diagnostic pipelines.</p>
<p>Herein lies the question for project liquid biopsies. The princess maxima centre has recently set up a whole exome sequencing (WES) for liquid biopsies of neuroblastoma patients, the same WES pipeline used for sequencing of cfDNA. Having the same pipeline allows them to compare the sequencing datasets of the patients to determine whether all aberrations found in tumour biopsy are also found in liquid biopsy. Furthermore, this allows them to study the heterogenicity of the tumour by the identification of aberrations that are present in the liquid biopsy, but not in the tumour biopsy. However, this comparison of the tumour and liquid biopsies is currently done manually, a laborious and time-consuming process. Thus, the assignment for this project is simple: using programming langauges, automate the comparisson of WES data of tumor and liquid biopsies.</p>

</div>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body hanging-indent">
<div id="ref-abelGainChromosomeArm1999" class="csl-entry">
Abel, F, K Ejeskär, P Kogner, and T Martinsson. 1999. <span>“Gain of Chromosome Arm 17q Is Associated with Unfavourable Prognosis in Neuroblastoma, but Does Not Involve Mutations in the Somatostatin Receptor 2 (<span>Sstr2</span>) Gene at 17q24.”</span> <em>British Journal of Cancer</em> 81 (8): 1402–9. <a href="https://doi.org/10.1038/sj.bjc.6692231">https://doi.org/10.1038/sj.bjc.6692231</a>.
</div>
<div id="ref-espositoNeuroblastomaTreatmentPostgenomic2017" class="csl-entry">
Esposito, Maria Rosaria, Sanja Aveic, Anke Seydel, and Gian Paolo Tonini. 2017. <span>“Neuroblastoma Treatment in the Post-Genomic Era.”</span> <em>Journal of Biomedical Science</em> 24 (February): 14. <a href="https://doi.org/10.1186/s12929-017-0319-y">https://doi.org/10.1186/s12929-017-0319-y</a>.
</div>
<div id="ref-louisNeuroblastomaMolecularPathogenesis2015" class="csl-entry">
Louis, Chrystal U, and Jason M Shohet. 2015. <span>“Neuroblastoma: <span>Molecular Pathogenesis</span> and <span>Therapy</span>.”</span> <em>Annual Review of Medicine</em> 66: 49–63. <a href="https://doi.org/10.1146/annurev-med-011514-023121">https://doi.org/10.1146/annurev-med-011514-023121</a>.
</div>
<div id="ref-marisRecentAdvancesNeuroblastoma2010" class="csl-entry">
Maris, John M. 2010. <span>“Recent <span>Advances</span> in <span>Neuroblastoma</span>.”</span> <em>The New England Journal of Medicine</em> 362 (23): 2202–11. <a href="https://doi.org/10.1056/NEJMra0804577">https://doi.org/10.1056/NEJMra0804577</a>.
</div>
<div id="ref-mlakar11qDeletionNeuroblastoma2017" class="csl-entry">
Mlakar, Vid, Simona Jurkovic Mlakar, Gonzalo Lopez, John M. Maris, Marc Ansari, and Fabienne Gumy-Pause. 2017. <span>“11q Deletion in Neuroblastoma: A Review of Biological and Clinical Implications.”</span> <em>Molecular Cancer</em> 16 (June): 114. <a href="https://doi.org/10.1186/s12943-017-0686-8">https://doi.org/10.1186/s12943-017-0686-8</a>.
</div>
<div id="ref-monclairInternationalNeuroblastomaRisk2009" class="csl-entry">
Monclair, Tom, Garrett M. Brodeur, Peter F. Ambros, Hervé J. Brisse, Giovanni Cecchetto, Keith Holmes, Michio Kaneko, et al. 2009. <span>“The <span>International Neuroblastoma Risk Group</span> (<span>INRG</span>) <span>Staging System</span>: <span>An INRG Task Force Report</span>.”</span> <em>Journal of Clinical Oncology</em> 27 (2): 298–303. <a href="https://doi.org/10.1200/JCO.2008.16.6876">https://doi.org/10.1200/JCO.2008.16.6876</a>.
</div>
<div id="ref-paraboschiRoleBiopsyWorkup2021a" class="csl-entry">
Paraboschi, Irene, Ester Bolognesi, Adele Giannettoni, Stefano Avanzini, Michele Torre, and Giuseppe Martucciello. 2021. <span>“The <span>Role</span> of <span>Biopsy</span> in the <span>Workup</span> of <span>Patients</span> with <span>Neuroblastoma</span>: <span>Comparison</span> of the <span>Incidence</span> of <span>Surgical Complications</span> and the <span>Diagnostic Reliability</span> of <span>Diverse Techniques</span>.”</span> <em>Children (Basel, Switzerland)</em> 8 (6): 500. <a href="https://doi.org/10.3390/children8060500">https://doi.org/10.3390/children8060500</a>.
</div>
<div id="ref-rifatbegovicEnrichedBoneMarrow2015" class="csl-entry">
Rifatbegovic, Fikret, M. Reza Abbasi, Sabine Taschner-Mandl, Maximilian Kauer, Andreas Weinhäusel, Rupert Handgretinger, and Peter F. Ambros. 2015. <span>“Enriched <span>Bone Marrow Derived Disseminated Neuroblastoma Cells Can Be</span> a <span>Reliable Source</span> for <span>Gene Expression Studies</span>.”</span> <em>PLoS ONE</em> 10 (9): e0137995. <a href="https://doi.org/10.1371/journal.pone.0137995">https://doi.org/10.1371/journal.pone.0137995</a>.
</div>
<div id="ref-whiteRegionConsistentDeletion1995" class="csl-entry">
White, P S, J M Maris, C Beltinger, E Sulman, H N Marshall, M Fujimori, B A Kaufman, J A Biegel, C Allen, and C Hilliard. 1995. <span>“<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC41727">A Region of Consistent Deletion in Neuroblastoma Maps Within Human Chromosome 1p36.2-36.3.</a>”</span> <em>Proceedings of the National Academy of Sciences of the United States of America</em> 92 (12): 5520–24.
</div>
<div id="ref-whittleOverviewRecentAdvances2017" class="csl-entry">
Whittle, Sarah B., Valeria Smith, Erin Doherty, Sibo Zhao, Scott McCarty, and Peter E. Zage. 2017. <span>“Overview and Recent Advances in the Treatment of Neuroblastoma.”</span> <em>Expert Review of Anticancer Therapy</em> 17 (4): 369–86. <a href="https://doi.org/10.1080/14737140.2017.1285230">https://doi.org/10.1080/14737140.2017.1285230</a>.
</div>
</div>
<p style="text-align: center;">
<a href="sql.html"><button class="btn btn-default">Previous</button></a>
<a href="open-reproductibility-analysis.html"><button class="btn btn-default">Next</button></a>
</p>
</div>
</div>


</div>

<script>

// add bootstrap table styles to pandoc tables
$(document).ready(function () {
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');
});

</script>

</body>
</html>
